Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback